AirSculpt Guides Above-Consensus Revenue; Bullish Stance On Oculis
- October 05th, 2023
- 664 views
AirSculpt Technologies, Inc. (Nasdaq: AIRS), a medical technology company specializing in body contouring procedures, has provided a positive outlook for its third-quarter 2023 revenue, with expectations set at approximately $46.5 million, surpassing the consensus estimate of $43.86 million.
Furthermore, the company has revised its full-year 2023 revenue guidance, anticipating approximately $196 million, up from the previous guidance range of $187 million to $192 million. The consensus revenue estimate stands at $192.23 million for the period.
In pre-market trading, $AIRS remains unchanged at $7.02.
In other news, Stifel has initiated coverage on Oculis Holding AG (Nasdaq: OCS), a notable player in the healthcare sector, granting it a Buy rating along with a price target of $35.
With $OCS closing at $11.07 on Wednesday, this price target implies a potential upside of $23.93 or approximately 216.09%, according to the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login